Tredje AP fonden Has $55.35 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Tredje AP fonden increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 6.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 137,452 shares of the pharmaceutical company's stock after purchasing an additional 7,978 shares during the period. Tredje AP fonden owned approximately 0.05% of Vertex Pharmaceuticals worth $55,352,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in VRTX. Truvestments Capital LLC raised its holdings in Vertex Pharmaceuticals by 30.3% in the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock valued at $40,000 after acquiring an additional 23 shares in the last quarter. Dunhill Financial LLC raised its holdings in Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company's stock valued at $27,000 after acquiring an additional 24 shares in the last quarter. Simon Quick Advisors LLC raised its holdings in Vertex Pharmaceuticals by 1.1% in the 4th quarter. Simon Quick Advisors LLC now owns 2,236 shares of the pharmaceutical company's stock valued at $900,000 after acquiring an additional 24 shares in the last quarter. Spinnaker Trust raised its holdings in shares of Vertex Pharmaceuticals by 2.1% in the 4th quarter. Spinnaker Trust now owns 1,235 shares of the pharmaceutical company's stock worth $497,000 after buying an additional 25 shares in the last quarter. Finally, Strategic Advisors LLC raised its holdings in shares of Vertex Pharmaceuticals by 0.6% in the 4th quarter. Strategic Advisors LLC now owns 4,486 shares of the pharmaceutical company's stock worth $1,807,000 after buying an additional 25 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.

Wall Street Analysts Forecast Growth

VRTX has been the subject of a number of recent research reports. William Blair reissued an "outperform" rating on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. Cantor Fitzgerald reissued an "overweight" rating and issued a $480.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Jefferies Financial Group raised Vertex Pharmaceuticals from a "hold" rating to a "buy" rating and increased their target price for the stock from $500.00 to $550.00 in a report on Monday, December 9th. Stifel Nicolaus increased their target price on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a "hold" rating in a report on Monday, December 16th. Finally, Oppenheimer cut Vertex Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Thursday, December 19th. Ten research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $506.70.

Remove Ads

Insider Activity

In other news, EVP David Altshuler sold 3,231 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the transaction, the executive vice president now owns 26,512 shares of the company's stock, valued at $13,256,000. This represents a 10.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Ourania Tatsis sold 530 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $475.34, for a total value of $251,930.20. Following the completion of the transaction, the executive vice president now directly owns 58,539 shares in the company, valued at approximately $27,825,928.26. This trade represents a 0.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 4,315 shares of company stock valued at $2,121,012 in the last 90 days. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Stock Up 1.4 %

Shares of VRTX opened at $495.42 on Thursday. The firm has a market capitalization of $127.22 billion, a price-to-earnings ratio of -225.19, a PEG ratio of 2.11 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The business's fifty day moving average price is $453.85 and its two-hundred day moving average price is $461.58. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. On average, analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.